Breast Cancer News and Research

Latest Breast Cancer News and Research

Peptide in blood and tissue inhibits growth of breast tumors

Researchers at Wake Forest University Baptist Medical Center (WFUBMC) have discovered what may become a new weapon in the fight against breast cancer. For the first time, a peptide found in blood and tissue has been shown to inhibit the growth of human breast tumors in mice, according to a study recently published in the journal Cancer Research.

4 Jan 2011

First whole genome sequence of Parsi breast cancer woman

Avesthagen Limited has yet again established its position as a leader in the successful application of next gen technologies as it announces the completion of the first Parsi breast cancer whole genome sequence of a 74-year-old Parsi woman with a heritable form of breast cancer. The incidence of breast cancer in most populations is strongly linked to a genetic basis but little is known about the variants at the present time.

4 Jan 2011

Cyfluent Chart, Version 2.0 receives Complete EHR certification

Cyfluent, Inc. announced today that Cyfluent Chart, Version 2.0, is 2011/2012 compliant and was certified as a Complete EHR on Friday, November 12, 2010 by the Certification Commission for Health Information Technology (CCHIT®), an ONC-ATCB, in accordance with the certification criteria adopted by the Secretary of Health and Human Services. The 2011/2012 criteria support the Stage 1 meaningful use measures required to qualify eligible providers and hospitals for funding under the American Recovery and Reinvestment Act (ARRA).

3 Jan 2011

Dosing initiated in combination Phase I study of palifosfamide with etoposide and cisplatin/carboplatin in SCLC

ZIOPHARM Oncology, Inc., announced today that the first patient has been dosed in a Phase I, single arm, dose escalation study at the Indiana University Cancer Center of intravenous (IV) palifosfamide (ZIO-201) in combination with etoposide (VP-16) and cisplatin/carboplatin (platinum) in the treatment of small cell lung cancer (SCLC) and other cancers.

29 Dec 2010

FDA approves Endo's FORTESTA Gel for low testosterone

Endo Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has approved FORTESTA Gel for the treatment of low testosterone, or 'Low T,' also known as hypogonadism. Symptoms associated with Low T include erectile dysfunction and decreased sexual desire, fatigue and loss of energy, mood depression, regression of secondary sexual characteristics and osteoporosis.

29 Dec 2010

Hormone enhanced meat taken off shelves at Coles

Hormonal growth enhancers banned three decades ago in Europe after being linked to health risks including breast cancer, kidney disease and birth defects are still being used in Australia to fatten beef, a federal farm chemical survey reveals.

28 Dec 2010

BIOMICs oversees SGIker DNA Bank to know genetic heritage of Basque lineage

The BIOMICs Group, based at the Lucio Lascaray building in the álava/Araba campus of the University of the Basque Country, is specially known for overseeing the SGIker DNA Bank, not only undertaking this task, but also feeding data into the gene research bank and making good use of it for their own lines of research.

28 Dec 2010

Breast cancer survival techniques for dealing with challenges on the job and in life

As Lecheler celebrates the New Year, she is sharing her breast cancer survival techniques with business executives and others who are looking for a resolution they can keep - having a healthier and happier 2011. Lecheler offers up her integrated healing tips in her new book The Spirit to Heal.

28 Dec 2010

Cancer survival rates improving

Survival rates for cancers of the bowel, breast, lung and ovary that were diagnosed between 1995 and 2007 were compared between Australia, Canada, Denmark, Norway, Sweden and the UK. Overall, survival rates improved in all six countries. However, survival was found to be “persistently lower” in Denmark, England, Northern Ireland and Wales. This was particularly the case after the first year of diagnosis and for patients aged 65 and over. In UK cancer survival rates have improved significantly. Breast cancer survival at five years, for example, increased from 74.8% in 1995-9, to 81.6% in 2005-7. Despite this, the UK still has the lowest breast cancer survival rate at five years.

27 Dec 2010

Earlier diagnosis in Cowden syndrome patients predisposed to breast and kidney cancer

Researchers at Cleveland Clinic's Genomic Medicine Institute have revealed multiple genetic discoveries that may permit easier diagnosis and disease management for Cowden syndrome patients who are predisposed to breast and kidney cancer.

23 Dec 2010

Patients with over expression of P-Rex1 protein are more likely to develop cancer metastasis

Overexpression or hyperactivation of ErbB cell-surface receptors drives the growth of many breast cancers. Drugs, like Herceptin, that block the receptors' signals halt tumor progression in some patients.

23 Dec 2010

Today's Opinions: Congressional funding vote leaves out health law; Price controls on health; Tough choices in Washington State

The Senate passed the Continuing Resolution 79-16 this afternoon. Another way of saying that: The Senate voted to defund the implementation of both health-care reform and financial-regulation reform.

23 Dec 2010

FDA approves Watson's novel oral contraceptive

Watson Pharmaceuticals today announced the U.S. Food and Drug Administration (FDA) approval of a novel oral contraceptive product – the first and only low dose oral contraceptive to combine 0.8 mg norethindrone and 0.025 mg ethinyl estradiol in chewable form, with four 75 mg ferrous fumarate (iron) placebo tablets. Taken orally, once daily, the product is proven effective in lowering the risk of pregnancy.

22 Dec 2010

New genetic alteration predisposes individuals to Cowden syndrome

Researchers have identified a new genetic alteration that predisposes individuals to Cowden syndrome, a rare disorder that is characterized by high risks of breast, thyroid and other cancers, according to preliminary research published in the December 22/29 issue of JAMA.

21 Dec 2010

DiaGenic issues notification of trade among insiders

On 17 December 2010 mandatory notification of trade among insiders of DiaGenic ASA took place.

20 Dec 2010

Take charge of your medical tests

Whether you're healthy or ill, there are a variety of medical tests your health care team might recommend for you. A yearly checkup often includes routine tests such as blood sugar and cholesterol levels, vision and hearing assessments, tests for heart functioning and others used to monitor a chronic condition—such as a lung function test for those with asthma.

20 Dec 2010

FDA moves to curb Avastin's approval for breast cancer

The Food and Drug administration on Thursday revoked its approval of Roche drug Avastin for the treatment of breast cancer. The agency's action, based on findings that did not confirm that the medicine helped patients with this disease, has drawn criticism from patients and politicians.

20 Dec 2010

Today's Opinions: Cucinelli argues for quickly moving Va. case to the Supreme Court; Unraveling Medicaid leaves a big gap; Taking away a cancer treatment

It's hard not to laugh at the cries over the "injustice" of forcing people to buy coverage. Working Americans are already forced to buy health coverage - but for others. They can't choose not to pay the Medicare payroll tax. They can't even make a deal with the government, promising, "I will forgo all future Medicare benefits if I can be freed from the Medicare payroll tax" (Froma Harrop, 12/16).

17 Dec 2010

First Edition: December 17, 2010

Today's headlines highlight major health policy developments, including action in a Florida courtroom regarding the 20-state challenge to the health law and the Food and Drug Administration's curb on Avastin for the treatment of breast cancer.

17 Dec 2010

Diagenic, Pfizer enter collaboration to identify biomarkers in early stages of Alzheimer's disease

DiaGenic ASA and Pfizer Inc today signed an agreement for explorative R&D collaboration to identify biomarkers in early stages of Alzheimer's disease (AD) using DiaGenic's patented gene expression technology and its blood samples from ongoing clinical studies.

17 Dec 2010